NCT06576037 2025-10-15Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial OriginM.D. Anderson Cancer CenterPhase 1 Recruiting128 enrolled